Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab maintenance dosing trial in advanced non-small cell lung cancer
2008-004454-33Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Oct 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck KGaA. Primary endpoint: Overall survival. Started Oct 2008; status: completed.
02
Drugs
cetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-004454-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004454-33.